EAST FALMOUTH, Mass. -- Associates of Cape Cod, Inc.
(ACC) announce that the Food and Drug Administration (FDA) has
cleared Glucatell, a serological assay that is intended for the qualitative
detection of beta-glucan in the serum of patients with symptoms of, or medical
conditions predisposing the patient to, invasive fungal infection and as an
aid in the diagnosis of deep seated mycoses and fungemias. ACC is a leading
manufacturer of endotoxin and beta-glucan detection products and a major
supplier to the pharmaceutical and medical device industries.
Glucatell, a serum test, measures (1,3)-beta-D-glucan, a fungal wall
compound that is shed into the blood during fungal infections. Glucatell
is sensitive to a few trillionths of a gram of (1,3)-beta-D-glucan. In a
recent study, Glucatell use resulted in a median of 12 days advance
indication of fungal infection, as compared with conventional diagnostic
procedures. Associates of Cape Cod, Inc. will be offering Glucatell in kit
form to reference laboratories, hospital laboratories and as a service in its
East Falmouth, Mass. CLIA laboratory.
Invasive fungal infection is a serious and life-threatening medical
condition. "With the addition of Glucatell to the ACC product line, we
move directly into a clinical market with a sensitive diagnostic that will
expedite care to patients predisposed to invasive fungal infections," said Dr.
A.J. Meuse, ACC president and CEO.
Associates of Cape Cod, Inc. is a leader in
the field of bacterial endotoxin and beta-glucan detection. A wholly owned
subsidiary of Seikagaku Corporation, the company pioneered the use of
Horseshoe Crab blood extract, Limulus Amebocyte Lysate (LAL), used in the
testing of pharmaceuticals, medical devices, and biologics, for the presence
of potentially toxic endotoxins and glucans. In 1977, the company was the
first to receive an FDA license for the manufacture of this reagent.
Source: Associates of Cape Cod, Inc.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.